Skip to main content
. 2017 Jun;56(6):708–715. doi: 10.1165/rcmb.2016-0154OC

Figure 1.

Figure 1.

IL-17A blockade attenuates rejection, fibrosis, and the development of obliterative bronchiolitis (OB). B10 left lungs were transplanted orthotopically into B6 recipients and were treated with either anti–IL-17A (17F3) or isotype control antibody on Days −2 and 0 and twice a week after transplant. Lungs were harvested and analyzed on Day 21. (A) Hematoxylin and eosin– (top panels) and Masson’s trichrome– (bottom panels) stained lung allografts; original magnification × 20. (B) Control and anti–IL-17A–treated allografts with severe acute rejection, fibrosis, (F4), and evidence of OB (arrow); top panels are hematoxylin and eosin and bottom panels are Masson’s trichrome; original magnification × 20. Scale bars: 200 μm. (C) Acute rejection (A score) and fibrosis (F score) in the allograft. (D) Prevalence of OB in the lung allografts (n = 13 [control], n = 20 [anti–IL-17A]). Data were analyzed using unpaired t test and two-tailed Fisher’s exact test in C and D, respectively; *P < 0.05, ***P < 0.001.